Leadership

Mr. Moroney is the Founder and President of Landmark Pegasus, Inc., and a seasoned business leader in both the Life Science and Healthcare industries, with extensive experience in corporate strategy, business development, finance and operational management.

Landmark was founded in 1983 and focused initially on development stage life science companies, with a special emphasis on generic drug companies. Among its early clients was Par Pharmaceutical (ENDO) , Sidmak Laboratories, Copley Pharmaceutical, Barr Laboratories, Zenith Pharmaceutical — now all part of TEVA.

Prior to founding Landmark, Mr. Moroney spent 10 years in commercial banking with Citibank, United Jersey Bank and Midlantic Banks, where he gained extensive experience in commercial lending and the use of the Economic Development Agency programs to fund emerging companies both in New Jersey and New York State.

Between 1985 and 1991 Landmark operated under an exclusive arrangement with Ladenburg Thalmann & Co., Inc., one of the oldest investment banks in New York, with Mr. Moroney serving as Managing Director of their Life Science group. During this period, Landmark served as investment banker to many noted Life Science companies, including the IPOs of Par Pharmaceutical, Alfin Fragrances, and Physicians Computer Network, Landmark also advised Columbia Laboratories on their IPO and their first product acquisition.

Landmark was also retained to restructure and finance Carrington Laboratories and MacroChem Laboratories. Mr. Moroney advised on Copley Pharmaceutical’s restructuring and subsequent private placement of equity and served as a director of the company until the sale of that interest to TA Associates. Landmark also introduced and advised F. Faulding & Co.Ltd., (Australia’s largest pharmaceutical company) on the acquisition of Solvay’s Purepac division.

In 1991, Ladenburg Thalmann underwent a change of ownership and management, and their exclusive arrangement with Landmark ended on amicable terms. While affiliated with Ladenburg, Mr. Moroney developed a unique service niche specializing in assisting foreign clients to become established in the US, and developing various strategies for U.S. market penetration. Landmark implemented a very successful strategy of cross border merger and acquisitions, licensing and joint ventures for their clients.

Through these assignments, Landmark has gained the trust and respect of our clients and they have experienced greater access to the capital markets which in turn has resulted in higher valuations and greater liquidity for them. During Landmark’s long history of servicing and advising clients in the healthcare arena, the Company has developed a vast network of both domestic and international industry relationships. Landmark’s clients have included Elan Pharmaceuticals, Fresenius, Ethypharm, Serono, Altana AG, Dynamit Nobel, and Drug Royalty Corp.

Starting in 1991, Landmark expanded their services to include the Nutrition industry, which today represents a large percentage of the company’s business. Clients have includes Nutrition21, Rexall Sundown, Balchem, Glanbia, Twin Labs (LBO) and a 25 year relationship with Pharmachem Laboratories, one of the largest branded ingredient manufacturer’s in the U.S. Medical Foods clients have included Medifast, Inc. (MED) and Pam Labs (Nestle).

Landmark continued their restructuring practice working with many companies like IGI Labs (Teligent – TLGT), Precision Optics, Inc (PEYE), American Bio Medica Corporation (ABMC), and Materials Processing Technology, Inc.

Mr. Moroney is also an experienced entrepreneur and investor, having active interests in pharmaceuticals, nutritionals, diagnostics and medical device companies. He was the co-founder of Flemington Pharmaceuticals, where he served for 10 years in various capacities including Chairman and CEO. He presided over the Company’s IPO and follow-on financings. He divested his holdings in 2003 with the completion of a financing to Paramount Capital. He was also the co-founder of Juvent Inc., a medical device company, Compliant Rx Solutions, Inc., a pharmaceutical services company, MD Diagnostics, and Dermworx Inc. Additionally, he served from 2010 to 2014 as the Chairman of Bedminster Financial Group Ltd., a licensed broker-dealer and member of FINRA, SIPIC and MSRB.

Mr. Moroney holds a B.S. and M.B.A. from Fordham University, and is a member of the Licensing Executives Society and the American Chemical Society.

Mr. Blomquist is a Managing Director with Landmark Pegasus Inc. and has over 30 years experience in all facets of corporate finance advisory work, having in particular extensive experience in complex financial modeling and analysis. As a Managing Director with Landmark since 1992, he has provided advisory services to a diverse international client base consisting of both well-established and emerging healthcare companies. Total transaction values have been in excess of $1 billion, and have included product and technology licensing, acquisitions and divestitures both of companies and product lines, leveraged buyouts, private placements of equity, initial public offerings, reorganizations, asset-based financing, venture capital financing, workouts, and various special projects. Currently, he also serves on a grant-writing team that has secured several million dollars in federal, state, and local grants for various municipal government entities in New York State.

Prior to joining Landmark, Mr. Blomquist served as a Senior Financial Analyst with both Ladenburg Thalmann & Company and Thomson McKinnon Securities, and held several positions with Chase Manhattan Bank. He holds a J.D. from Tulane Law School, where he served as a research assistant on M. David Gelfand’s State and Local Government Debt Financing treatise, considered the leading work in the field; an M.B.A. in International Finance (with Honors) from St. John’s University, where he graduated at the head of his class, and a B.A. in History from the University of New York at Albany. He is a CFA Charter holder, and a member of CFA Institute, the New York Society of Securities Analysts, the American Finance Association, and the Licensing Executives’ Society. He has been admitted to both the Louisiana and New York State Bars.

Dr. Saccomanno has over 20 years experience in corporate and entrepreneurial sales, marketing and business development in the life sciences. She currently serves as a consultant to a broad range of bio- pharmaceutical clients, with a focus on projects involving pharmacovigilance and safety risk management subject matter expertise and global, cross-functional project management. Her past experience includes positions at Hoffmann-La Roche, Inc., where she advised and assisted product teams in best practices related to safety risk management, safety signal detection, and comparative benefit-risk assessment, and various account management and business development positions with Thermo Fisher Scientific, Covance Laboratories, Inc., Vysis, Inc. (now Abbott Molecular), and Bio-Rad Laboratories, Inc.Dr. Saccomanno’s experience also includes management roles at several life science start-ups, including DrugLogic Inc., Gene Express Inc., and Resolution Sciences. Dr. Saccomanno holds a Ph.D. in Molecular Biology and MS and BS degrees in the sciences from Fordham University, as well as an MSLIS from the Pratt Institute. She is also a noted speaker and author in the life sciences field.

Mr. Klaucke is a Principal with Landmark Pegasus Inc. supporting its mergers and acquisitions, strategic partnerships, capital raising, and corporate finance efforts across a variety of healthcare and life science sectors. He is responsible for originating, evaluating, executing and managing transactions and consulting engagements.

Prior to joining Landmark, Mr. Klaucke was a Senior Consultant with a national corporate finance advisory firm where he was responsible for the firm’s business development efforts as well as leading and managing consulting engagements, which included extensive due diligence and financial analysis. He worked directly with CEOs and CFOs of large publicly traded and privately held companies nationwide.

Mr. Klaucke began his career with PricewaterhouseCoopers LLP in the assurance and transaction advisory practices. While a member of the assurance practice, his primary client focus was sizeable hedge funds, private equity funds, and publicly listed conglomerates. He draws upon his past experience working with Fortune 10 and Fortune 50 companies completing international cross-boarder M&A transactions as a member of the transaction advisory practice. He is an actively licensed CPA in the state of Florida and a member of the AICPA.

Mr. Klaucke was a Coca-Cola Scholar and graduated magna cum laude with a B.S. and M.S. from The University of Tampa. He is a very active member of the local business community as a member of the Association for Corporate Growth and a volunteer for the Florida Council on Economic Education. Mr. Klaucke also currently serves as a Trustee of The University of Tampa.